Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design

OBJECTIVE: Sinemet, a combination drug containing carbidopa and levodopa is considered the gold standard therapy for the treatment of Parkinson's disease (PD). When approved by the Food and Drug Administration (FDA) in 1988, a maximum daily dosage limit of 800 mg (eight tablets) of the 25/100 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodell, David W, Stanford, Nicole T, Jacobson, Charles E, Schmidt, Peter, Okun, Michael S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2012
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533055/
https://www.ncbi.nlm.nih.gov/pubmed/23233700
http://dx.doi.org/10.1136/bmjopen-2012-001971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533055/
https://www.ncbi.nlm.nih.gov/pubmed/23233700
http://dx.doi.org/10.1136/bmjopen-2012-001971

Ejemplares similares